Selected article for: "acute ards respiratory distress syndrome and lower mortality"
Author: Alexaki, Vasileia Ismini; Henneicke, Holger
Title: The Role of Glucocorticoids in the Management of COVID-19
  • Cord-id: pmay2kfn
  • Document date: 2020_11_18
    • ID: pmay2kfn
    Snippet: Coronavirus disease 2019 (COVID-19), caused by an infection with the novel coronavirus SARS-CoV-2, has resulted in a global pandemic and poses an emergency to public health systems worldwide. COVID-19 is highly infectious and is characterized by an acute respiratory illness that varies from mild flu-like symptoms to the life-threatening acute respiratory distress syndrome (ARDS). As such, there is an urgent need for the development of new therapeutic strategies, which combat the high mortality i
    Document: Coronavirus disease 2019 (COVID-19), caused by an infection with the novel coronavirus SARS-CoV-2, has resulted in a global pandemic and poses an emergency to public health systems worldwide. COVID-19 is highly infectious and is characterized by an acute respiratory illness that varies from mild flu-like symptoms to the life-threatening acute respiratory distress syndrome (ARDS). As such, there is an urgent need for the development of new therapeutic strategies, which combat the high mortality in severely ill COVID-19 patients. Glucocorticoids are a frontline treatment for a diverse range of inflammatory diseases. Due to their immunosuppressive functions, the use of glucocorticoids in the treatment of COVID-19 patients was initially regarded with caution. However, recent studies concluded that the initiation of systemic glucocorticoids in patients suffering from severe and critical COVID-19 is associated with lower mortality. Herein we review the anti-inflammatory effects of glucocorticoids and discuss emerging issues in their clinical use in the context of COVID-19.

    Search related documents:
    Co phrase search for related documents
    • action mechanism and acute respiratory illness: 1, 2, 3, 4
    • action mechanism and adaptive immune system: 1
    • action mechanism and adhesion molecule: 1, 2, 3
    • action mechanism and adhesion molecule expression: 1
    • action mechanism and adrenal pituitary: 1
    • action mechanism and low medium: 1
    • action mechanism and low mortality: 1
    • action mechanism and lung respiratory tract: 1
    • action mechanism and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • action mechanism and lymphocyte neutrophil: 1
    • action mechanism and lymphocyte neutrophil ratio: 1
    • activation ards and acute ards respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32
    • activation ards and acute respiratory illness: 1
    • activation ards and lung tissue: 1, 2, 3
    • activation ards and macrophage inflammatory activation: 1
    • activator protein and acute ards respiratory distress syndrome: 1, 2, 3, 4, 5, 6